What's Happening?
ImmunityBio, Inc., a commercial-stage immunotherapy company, announced an expanded FDA approval for its drug ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG). The expanded indication now includes adult patients
with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with high-grade papillary-only tumors. This approval, granted on October 14, 2026, broadens the treatment options for a significant patient population. The company also reported strong financial performance for the third quarter of 2026, with net product revenue reaching $48.7 million, a 53% increase year-over-year. Year-to-date net product revenue for 2026 totaled $143.6 million, marking a 92% increase compared to the first nine months of 2025. ImmunityBio also achieved global expansion, with ANKTIVA now approved or authorized in six regulatory jurisdictions, covering 35 countries. Furthermore, the primary endpoint for Cohort A of the randomized QUILT-2.005 trial in BCG-naïve NMIBC patients was met, and a supplemental Biologics License Application (sBLA) is on track for submission in Q4 2026.
Why It's Important?
The expanded FDA approval for ANKTIVA is a significant development for patients with BCG-unresponsive NMIBC, particularly those with papillary-only tumors, offering a new chemotherapy-free immunotherapy approach. This broadens the market for ANKTIVA in the U.S. and reinforces its clinical utility. The strong revenue growth reported by ImmunityBio, with a 53% year-over-year increase in Q3 net product revenue and a 92% increase year-to-date, demonstrates successful commercialization and increasing adoption of ANKTIVA by U.S. urologists. The global expansion into 35 countries further solidifies the company's market presence and potential for future growth. The positive results from the QUILT-2.005 trial for BCG-naïve NMIBC patients suggest that ANKTIVA's applicability could extend to an even larger patient population, potentially transforming the standard of care for early-stage bladder cancer. These advancements highlight ImmunityBio's role in developing innovative immunotherapies and addressing critical unmet medical needs in oncology.
What's Next?
ImmunityBio plans to submit a supplemental Biologics License Application (sBLA) to the FDA in the fourth quarter of 2026 for ANKTIVA in combination with BCG for patients with BCG-naïve NMIBC, following positive results from the QUILT-2.005 trial. This submission could further expand ANKTIVA's approved indications and market reach. The company will also pursue global filings for the expanded indication of ANKTIVA in BCG-unresponsive NMIBC, building on its recent approval in Israel and the first patient treatments in Europe. ImmunityBio intends to initiate real-world evidence studies to further characterize ANKTIVA's clinical impact in NMIBC. Additionally, the company will continue to advance its clinical programs in metastatic non-small cell lung cancer, GBM, and hematologic malignancies, indicating a broader pipeline development strategy beyond bladder cancer.
Beyond the Headlines
The success of ANKTIVA in NMIBC, particularly its chemotherapy-free approach, represents a significant shift in cancer treatment paradigms, moving towards immunotherapies that harness the body's own immune system. The long-term complete response rates observed in the QUILT-3.032 trial, extending beyond 3.5 years, underscore the potential for durable efficacy with ANKTIVA. This could reduce the need for more invasive procedures like cystectomy, improving patients' quality of life. The company's focus on expanding its Cancer BioShield™ platform, which aims to stimulate critical lymphocytes, suggests a broader strategy to develop treatments for various cancers and infectious diseases. The financial health and global expansion of ImmunityBio indicate a growing influence in the biotechnology sector, potentially attracting further investment and partnerships to accelerate the development of its diverse immunotherapy pipeline.
